• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Pharma & Human Health

Enterome Enters Research Collaboration Focused on Microbiome-derived Immunotherapies

November 7, 2019 Microbiome Times

Enterome, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics, has entered into a research collaboration with […]

Finance

OraSure Technologies, Inc. Announces Purchase of Diversigen

November 7, 2019 Microbiome Times

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, today announced that it has entered into a definitive agreement to acquire the outstanding equity of Diversigen […]

Pharma & Human Health

Even the fetus has gut bacteria, study shows

November 2, 2019 Microbiome Times

A study in humans and mice demonstrated that a fetus has its own microbiome, or communities of bacteria living in the gut, which are known to play important roles in the immune system and metabolism. […]

Finance

Chardan Healthcare Acquisition Corp. Completes Merger with BiomX Ltd.

November 2, 2019 Microbiome Times

Chardan Healthcare Acquisition Corp. (NYSE: CHAC), a special purpose acquisition company sponsored by affiliates of Chardan Capital Markets LLC (“Chardan”), announced today the closing of its merger with BiomX Ltd. (“BiomX”) a microbiome company developing […]

Finance

Arranta Bio announces $82M in new funding, and a strategic partnership with Thermo Fisher Scientific

November 2, 2019 Microbiome Times

Arranta Bio (“Arranta”) announced the completion of an $82 million funding round and a strategic partnership with Thermo Fisher Scientific. Formed in May 2019, Arranta’s goal is to be the best-in-class microbiome contract development and […]

Editor's Choice

Group examines the unique challenges of clinical trials for development of microbiotic medicinal products, including live biotherapeutic products

October 29, 2019 Kristina Campbell

Many individuals living with chronic disease—whether it’s asthma, allergies, atopic dermatitis, type 2 diabetes, or another condition—readily confirm their therapeutic options leave a lot to be desired. Even if an existing drug product deals adequately […]

Pharma & Human Health

Half of all commonly used drugs profoundly affecting the gut microbiome, warn experts

October 26, 2019 Microbiome Times

A new study presented at UEG Week 2019 has found that 18 commonly used drug categories extensively affect the taxonomic structure and metabolic potential of the gut microbiome. Eight different categories of drugs were also […]

Editor's Choice

Standardization in microbiome measurements Considerations from sampling to analysis

October 25, 2019 Microbiome Times
Pharma & Human Health

Phage lysin stabilizes vaginal microbiome: Phagomed accelerates R&D program against bacterial vaginosis.

October 23, 2019 Microbiome Times

Vienna-based biotech company PhagoMed Biopharma GmbH has discovered a novel drug candidate for the treatment of Bacterial Vaginosis and the re-stabilization of the vaginal microbiome. A dedicated R&D team has been established to develop this […]

Editor's Choice

The Lactobacillus Taxonomy change is coming: why, and how to make the most of it?

October 17, 2019 Marco Pane and Nina Vinot

1. What is taxonomy, what’s the reality behind it – and why do we need it anyway? Taxonomy is the branch of science concerned with the classification of organisms. Since Darwin, it has allowed to […]

Editor's Choice

Toward Clinical Utility of Metagenomic Data: Interview with Dr Joël Doré

October 17, 2019 Microbiome Times

Posts navigation

« 1 … 53 54 55 … 85 »

Sign Up to Free Newsletter

Editor’s Choice

  • Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
    November 17, 2025
  • The OMNIgene™•VAGINAL device – Optimized solutions for vaginal microbiome studies
    November 12, 2025
  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
sign up

Sign up to the Microbiome Times newsletter